Feb 24, 2020

Proceedings from Part 1 of a 2-part satellite symposia series during the 61st ASH Annual Meeting. Featuring perspectives from Dr Jeremy Abramson, Dr Bruce D Cheson, Prof John G Gribben, Dr Brad S Kahl, Dr Loretta Nastoupil and Dr Laurie H Sehn.

• Introduction
• • Program Overview: Dr Love (00:00)
• Evolving Therapeutic Algorithms for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL)
• • Case (Dr Khan): A man in his late 40s with IGHV-mutated CLL who achieves a complete remission with first-line FCR but experiences multiple toxicities (01:26)
  • Case (Dr Peswani): A man in his late 70s who presents with highly symptomatic CLL requiring an immediate response to treatment (10:36)
  • Faculty Presentation: Dr Kahl (18:19)
• Management of Relapsed/Refractory (R/R) CLL and Novel Investigational Approaches
• • Case (Dr Kale): A woman in her late 70s with small lymphocytic lymphoma who is hospitalized for the initial cycles of venetoclax/obinutuzumab because of poor renal function (31:50)
  • Case (Dr Lamar): A man in his early 70s with CLL who receives ibrutinib and develops atrial fibrillation and hematuria requiring dose reduction (39:25)
  • Faculty Presentation: Prof Gribben (46:38)
• Contemporary Management of Newly Diagnosed and R/R Follicular Lymphoma (FL)
• • Case (Dr Kale): A man in his mid-70s with Stage III FL and multiple comorbidities who experiences a prolonged response to rituximab monotherapy (1:00:14)
  • Additional questions from the community oncologist/hematologist panel regarding the management of FL (1:03:34)
  • Faculty Presentation: Dr Cheson (1:12:05)
• Protocol and Off-Protocol Care for Patients with Mantle Cell Lymphoma (MCL)
• • Case (Dr Peswani): A man in his early 70s who is diagnosed with MCL with gastrointestinal involvement (1:24:13)
  • Additional questions from the community oncologist/hematologist panel regarding the management of MCL (1:28:31)
  • Faculty Presentation: Dr Abramson (1:33:51)
• Recent Breakthroughs and Other Promising Approaches in the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
• • Case (Dr Brenner): A woman in her mid-80s with DLBCL and a performance status of 2 who receives R-mini-CHOP but experiences disease progression after 4 months (1:47:02)
  • Case (Dr Morganstein): A man in his early 60s with triple-hit DLBCL (1:52:35)
  • Faculty Presentation: Dr Sehn (1:55:18)
• Integration of CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy into the Management of Lymphomas
• • Questions from the community oncologist/hematologist panel regarding CAR T-cell therapy (2:08:34)
  • Case (Dr Morganstein): A man in his early 40s with DLBCL who receives CAR T-cell therapy after no response to up-front R-CHOP and disease progression after salvage chemotherapy followed by ASCT (2:13:19)
  • Faculty Presentation: Dr Nastoupil (2:16:08)

CME information and select publications